Investor Relations

SEC Filings

  • View CEL-SCI's SEC Filings  
       
  • View CEL-SCI's Section 16 Filings  

Stock Quotes

  • NYSE AMEX  

Corporate Presentation

  • View CEL-SCI Presentation  

Press Releases

  • Press Releases  
  FEBRUARY 3, 2010
09:00 AM NEW STORY CEL-SCI To Present At 12TH Annual BIO CEO & Investor Conference
  JANUARY 15, 2010
09:35 AM NEW STORY CEL-SCI Hires Vice President Of Manufacturing/Facilities And Commercial Operations
  JANUARY 13, 2010
04:20 PM NEW STORY CEL-SCI Corporation Announces 2009 Financial Results
  JANUARY 11, 2010
09:30 AM NEW STORY CEL-SCI Completes Validation Of Manufacturing Facility Allowing It To Commence Manufacturing Of Multikine
  DECEMBER 1, 2009
10:15 AM CEL-SCI Retains Global Contract Research Organization To Manage Upcoming Phase III Clinical Trial For Its Cancer Drug Multikine
  NOVEMBER 18, 2009
09:45 AM CEL-SCI Announces Start Of First Clinical Study Of Investigational LEAPS-H1N1 Treatment For Hospitalized H1N1 Infected Patients At Johns Hopkins University School Of Medicine
  NOVEMBER 9, 2009
09:40 AM CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability To Modify Immune Response
  NOVEMBER 6, 2009
09:45 AM CEL-SCI To Conduct First Clinical Study Of Investigational LEAPS-H1N1 Treatment For Hospitalized H1N1 Infected Patients At Johns Hopkins University School Of Medicine
  OCTOBER 26, 2009
09:55 AM CEL-SCI Corporation Strengthens Balance Sheet Through Receipt Of $10 Million From Warrant Exercises

Letter to Shareholders

  • Letter to Shareholders  

Read the latest research report on CEL-SCI

  • Research Report  

Investor Relations Contact

   

Gavin de Windt
Phone: +1 703-506-9460
E-mail: gdewindt@cel-sci.com

 

 

 

Research &
Clinical Trials

 

  

SEC Filings